Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way disease is treated. Orna's proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions. oRNA has many advantages over traditional mRNA approaches, including simplified production, improved formulatability, and superior protein expression - making it a highly disruptive, new class of RNA therapeutics with vast potential to change patient's lives.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
02/24/21	$80,000,000	Series A	Astellas Venture Management Bristol-Myers Squibb F2 Ventures Kite Ventures MPM Capital Novartis Institute for Biomedical Research PAGS Group Taiho Ventures	undisclosed
08/16/22	$221,000,000	Series B	BioImpact Capital Merck MPM Capital	undisclosed